Apellis Pharmaceuticals, Inc. (APLS) Misses Q3 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Apellis Pharmaceuticals Reports Third Quarter 2022 Financial Results
November 7, 2022 4:05 PM ESTPlans to submit 24-month Phase 3 data to the FDA for intravitreal pegcetacoplan for geographic atrophy (GA); expected PDUFA target action date in February 2023EU marketing authorization application submission on track for December 2022Reported 24-month data with pegcetacoplan in GA showing increased effects over time and continued favorable safety profileAchieved $17.7 million in Q3 2022 EMPAVELI® (pegcetacoplan) U.S. net product revenuesCash and investments of $708.6 million as of Sept. 30, 2022; expected cash runway into Q1 2024Conference call scheduled today at 4:30 p.m. ET
WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) --... More
